Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 2/20 | 0.36 |
| ▸ | NPY4R | P50391 | 10/20 | 0.35 |
| ▸ | NPY1R | P25929 | 7/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.35 |
| ▸ | NPY2R | P49146 | 3/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21532917 | 0.87 | CACNA1B (0.43) | KISS1RNPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL22139606 | 0.86 | NPY4R (0.39) | KISS1RNPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL20997114 | 0.86 | NPY4R (0.39) | KISS1RNPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL20997126 | 0.86 | NPY4R (0.37) | KISS1RNPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL20997320 | 0.84 | C3AR1 (0.34) | NPY4RNPY1RNPY5RNPY2RC3AR1 | |
| SCHEMBL25464237 | 0.83 | DPP7 (0.39) | NPY4RNPY1RNPY5RNPY2RC3AR1 | |
| SCHEMBL19401707 | 0.83 | DPP7 (0.39) | NPY4RNPY1RNPY5RNPY2RC3AR1 | |
| SCHEMBL19687789 | 0.83 | DPP7 (0.39) | NPY4RNPY1RNPY5RNPY2RC3AR1 | |
| SCHEMBL19698084 | 0.81 | C3AR1 (0.39) | NPY4RNPY1RNPY5RNPY2RC3AR1 | |
| SCHEMBL19703679 | 0.81 | NMT2 (0.32) | KISS1RNPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464969-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | NOVARTIS AG (CH) | 2019-11-05 | — | — | US | disclosed |
| US-20190144504-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464969-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | RNGTT, RNASE1, RNMT | KISS1R 2930/4885NPY4R 3873/4885NPY1R 2894/4885 |
| US-20190144504-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | KISS1R 2930/4885NPY4R 3873/4885NPY1R 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.